Mydecine Innovations Group an emerging biopharma and life sciences company committed to the research, development, and acceptance of alternative nature-sourced therapeutic medicine for mainstream use, announced that it is sponsoring a study titled: “The neurocognitive effects of low dose psychoactive substances,” at Australia’s Macquarie University The research, led by Principal Investigator Dr. Vince Polito, …

Mydecine Innovations Group (CSE: MYCO) (OTC: MYCOF) (FSE: 0NFA) (“Mydecine” or the “Company”), an emerging biopharma and life sciences company committed to the research, development, and acceptance of alternative nature-sourced therapeutic medicine for mainstream use, announced that it is sponsoring a study titled: “The neurocognitive effects of low dose psychoactive substances,” at Australia’s Macquarie University

The research, led by Principal Investigator Dr. Vince Polito, Senior Research Fellow at the Department of Cognitive Science at Macquarie University, is the first study of naturalistic microdosing in a lab setting. Previous studies have either relied on surveys of microdosers or have given people who have not microdosed before a single controlled dose. In this study people who already have an established practice of microdosing will come to the lab to complete a cutting-edge battery of measures.

“Our focus of the study is exploring whether microdosing leads to changes in novelty perception or pattern recognition,” said Dr. Polito. “In exploring the experiences of genuine microdosers from multiple angles, looking at behavioural, neuroimaging and biomarker data, we want to discover what actually happens when people microdose ‘in the wild’ and whether we can find objective indicators of some of the benefits that microdosers claim.”

The study will also be the first to use Magnetoencephalography, or MEG scans, to identify brain activity, along with planned cognitive and biometric measures, while microdosing.

“This study will further shed light on currently ambiguous effects of microdosing,” said Josh Bartch, CEO and Co-Founder of Mydecine. “Microdosing has a strong following of self-administering users, but actual medical data is currently thin. By applying scientific rigor like this, along with the ongoing work at the Imperial College London, we are helping to build a library of solid data sets that begin to tell us how microdosing works, and how it can be used in future clinical trials for various mental health issues.”

Dr. Polito is a Research Fellow in the Department of Cognitive Science at Macquarie University. His focus is on self representation and developing measures of how our sense of self changes in different contexts, clinical conditions, and altered states of consciousness.

About Mydecine Innovations Group

Mydecine Innovations Group™ is a life sciences company dedicated to developing and commercializing innovative solutions for treating mental health problems and enhancing wellbeing. The company’s world-renowned medical and scientific advisory board is progressing a robust R&D pipeline of psychedelic derived therapeutics, novel compounds, therapies, and controlled drug delivery systems. Mydecine has exclusive access to a full cGMP certified pharmaceutical manufacturing facility with the ability to import/export, extract, and analyze natural and synthetic psychedelic compounds with full government approval through Health Canada. Mydecine’s portfolio companies Mydecine Health Sciences™, Mindleap Health™, and NeuroPharm™ position the company at the forefront of disruptive modern medicine.

Learn more at: https://www.mydecine.com/ and follow us on Facebook , Twitter , and Instagram .

Mydecine Innovations Group Media Contacts
Anne Donohoe / Nick Opich
KCSA Strategic Communications
adonohoe@kcsa.com / nopich@kcsa.com
212-896-1265 / 212-896-1206

On behalf of the Board of Directors:
Joshua Bartch, Chief Executive Officer
contact@mydecineinc.com

Corp Communication:
Charles Lee, Investor Relations
corp@mydecineinc.com
+1 720-277-9879

For further information about Mydecine Innovations Group, Inc., please visit the Company’s profile on SEDAR at www.sedar.com or visit the Company’s website at www.mydecine.com .

The Canadian Securities Exchange has neither approved nor disapproved the contents of this news release and accepts no responsibility for the adequacy or accuracy hereof. This news release contains forward-looking statements, which relate to future events or future performance and reflect management’s current expectations and assumptions. Such forward-looking statements reflect management’s current beliefs and are based on assumptions made by and information currently available to the Company. Readers are cautioned that these forward-looking statements are neither promises nor guarantees, and are subject to risks and uncertainties that may cause future results to differ materially from those expected including, without limitation, the availability and continuity of financing, the ability of the Company to adequately protect and enforce its intellectual property, the Company’s ability to bring its products to commercial production, continued growth of the global adaptive pathway medicine, natural health products and digital health industries, and the risks presented by the highly regulated and competitive market concerning the development, production, sale and use of the Company’s products. Although the Company has attempted to identify important factors that could cause actual results to differ materially from those contained in forward-looking information, there may be other factors that cause results not to be as anticipated, estimated or intended. There can be no assurance that such information will prove to be accurate, as actual results and future events could differ materially from those anticipated in such information. These forward-looking statements are made as of the date hereof and the Company does not assume any obligation to update or revise them to reflect new events or circumstances save as required under applicable securities legislation. This news release does not constitute an offer to sell securities and the Company is not soliciting an offer to buy securities in any jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of such jurisdiction. This news release does not constitute an offer of securities for sale in the United States. These securities have not and will not be registered under United States Securities Act of 1933, as amended, or any state securities laws and may not be offered or sold in the United States or to a U.S. Person unless so registered, or an exemption from registration is relied upon.


Primary Logo

News Provided by GlobeNewswire via QuoteMedia

SHAREHOLDER ALERT: WeissLaw LLP Investigates Square, Inc.

WeissLaw LLP is investigating possible breaches of fiduciary duty and other violations of law by the board of directors of Square, Inc. (“Square”) (NYSE: SQ) in connection with the Company’s proposed acquisition of Afterpay Limited (“Afterpay” or the “Company”) (ASX: APT). Under the terms of the agreement, Square will issue shares of Square’s Class A common stock to Afterpay shareholders, who will receive 0.375 shares of Square stock for each Afterpay share they own. The transaction is valued at approximately $29 billion .

Keep reading... Show less

Australia Resource Investing 101

If you’re reading this, chances are you’ve seen some of the recent buzz around Australia as a destination for resource investment and potential profit.

Australia ranks as the 13th largest economy in the world, due in no small part to its mineral largess. Between 2010 and 2020, mining contributed an impressive 10.4 percent to Australia’s economy, translating to a gross domestic product of AU$202 billion.

The country is a global mining hotspot, and its abundant natural resources and government incentives have attracted some of the mining industry’s biggest names: BHP (ASX:BHP,LSE:BHP,NYSE:BHP), Rio Tinto (ASX:RIO,LSE:RIO,NYSE:RIO) and Newcrest Mining (ASX:NCM,OTC Pink:NCMGF).

Keep reading... Show less

Blackstone Board Approves Pilot Plant and Ta Khoa Refinery DFS

Following compelling outcomes from the Ta Khoa Refinery (TKR) Pre-Feasibility Study (refer ASX announcement 26 July 2021), Blackstone Minerals ("Blackstone" or the "Company") Board of Director's have approved the first phase of pilot plant work and the Definitive Feasibility Study (DFS) for the TKR.

Keep reading... Show less

Elevate Uranium: Carbon Free Energy

Elevate Uranium Limited (ASX:EL8) specializes in identifying, exploring and acquiring highly prospective uranium projects in Australia and Namibia. With a management team having more than 60 years of experience in the uranium sector, the company is the largest tenement holder for uranium in Namibia, which is the fourth-highest uranium-producing country in the world as of 2019.

Keep reading... Show less

Galaxy Resources Limited Announcement

Galaxy Resources Limited (ASX: GXY) ( Company ) advises that the following announcement has been made to the Australian Securities Exchange which appears on the Company’s platform (ASX):

  • Change in directors interest notice – MR

The announcement can be viewed at:

Keep reading... Show less

SHAREHOLDER ALERT: WeissLaw LLP Investigates Afterpay Limited

WeissLaw LLP is investigating possible breaches of fiduciary duty and other violations of law by the board of directors of Afterpay Limited (“Afterpay” or the “Company”) (ASX: APT) in connection with the Company’s proposed acquisition by Square, Inc. (“Square”) (NYSE: SQ) by way of a Scheme of Arrangement. Under the terms of the agreement, Afterpay shareholders will receive 0.375 shares of Square stock for each Afterpay share they own, representing implied per-share merger consideration of approximately $92.72 based upon Square’s July 30, 2021 closing price of $247.26 . Square may elect to pay 1% of total consideration in cash. The transaction is valued at approximately $29 billion .

Keep reading... Show less

Top News

Related News